Metformin as firstline treatment for type 2 diabetes: Are we sure?

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Boussageon, Rémy ^a   Gueyffier, François ^b,c   Cornu, Catherine ^b,c,d  

^a Laboratory of the Physiologically Adapted to the Physical Activities   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LYON   (France)

^d Inserm   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; MEAN ARTERIAL PRESSURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; DIABETES MELLITUS, TYPE 2; PRACTICE GUIDELINE; STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PRACTICE GUIDELINES AS TOPIC;

EID: 84959478814     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h6748     Document Type: Article

References (27)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
3. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
4. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Plos Med 2012;9:e1001204.
5. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-603.
6. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. BMJ 2001;323:854-8.
7. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998;352:832-3.
8. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;339:b2680.
9. Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomised clinical trials. Diabetes Obes Metab 2011;13:221-8.
10. Hróbjartsson A, Thomsen AS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;27;344:e1119.
11. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007;2:MR000012.
12. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
13. Moyé LA. Multiple analyses in clinical trials. Fundamentals for investigators. Springer-Verlag, 2003.
14. Boussageon R, Supper I, Erpeldinger S, et al. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? A systematic review. BMC Med Res Methodol 2013;13:107.
15. Mühlhauser I. Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2009;360:417.
16. Holman RR, Matthews DR, Neil HA. Follow-up of intensive glucose control in type 2 diabetes. The authors reply. N Engl J Med 2009;360:416-8.
17. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
18. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1975;24(suppl 1):65-184.
19. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
20. Fitzgerald E, Mathieu S, Ball A. Metformin associated lactic acidosis. BMJ 2009;339:b3660.
21. Hung SC, Chang YK, Liu JS, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol 2015;3:605-14.
22. De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181.
23. Huang W, Castelino RL, Peterson GM. Adverse event notifications implicating metformin with lactic acidosis in Australia. J Diabetes Complications 2015;29:1261-5.
24. Chowdhury TA, Wright R, Yaqoob MM. Using metformin in the presence of renal disease. BMJ 2015;350:h1758.
25. Scirica BM, Bhatt DL, Braunwald E, et al. NCT01107886: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
26. Boussageon R, Gueyffier F, Cornu C. Effects of pharmacological treatments on microand macrovascular complications of type 2 diabetes: what is the level of evidence? Diabetes Metab 2014;40:169-75.
27. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 Sep 17. [Epub ahead of print]